Advertisement
Gynecologic Oncology
Advanced searchSave search
Research Article| Volume 151, ISSUE 2, P229-234, November 2018

Download started.

Ok

SPERANZA project: HPV vaccination after treatment for CIN2+

Published:September 06, 2018DOI:https://doi.org/10.1016/j.ygyno.2018.08.033
SPERANZA project: HPV vaccination after treatment for CIN2+
Previous ArticleDurability of clinical performance afforded by self-collected HPV testing: A 15-year cohort study in China
Next ArticleMulticenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy

      Highlights

      • •
        After conization, HPV vaccine shows 80% clinical effectiveness in disease relapse prevention.
      • •
        Clinical benefits of vaccination are demonstrated up to 4 years.
      • •
        HPV vaccine has no therapeutic effect on prevalent HPV infection or disease.
      • •
        HPV vaccination is beneficial as an adjuvant additional to surgical treatment.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

      1. Human Papilloma Virus Vaccines: WHO Position Paper. Weekly Epidemiological Record, No. 15. 84. 2009: 117-132
        View in Article
        • Stanley M.A.
        Human papillomavirus vaccines.
        Rev. Med. Virol. 2006 May–Jun; 16: 139-149
        View in Article
        • Olsson S.E.
        • Kjaer S.K.
        • Sigurdsson K.
        • Iversen O.E.
        • Hernandez-Avila M.
        • Wheeler C.M.
        • Perez G.
        • Brown D.R.
        • Koutsky L.A.
        • Tay E.H.
        • García P.
        • Ault K.A.
        • Garland S.M.
        • Leodolter S.
        • Tang G.W.
        • Ferris D.G.
        • Paavonen J.
        • Lehtinen M.
        • Steben M.
        • Bosch F.X.
        • Dillner J.
        • Joura E.A.
        • Majewski S.
        • Muñoz N.
        • Myers E.R.
        • Villa L.L.
        • Taddeo F.J.
        • Roberts C.
        • Tadesse A.
        • Bryan J.
        • Maansson R.
        • Vuocolo S.
        • Hesley T.M.
        • Saah A.
        • Barr E.
        • Haupt R.M.
        Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection.
        Hum. Vaccin. 2009 Oct; 5: 696-704
        View in Article
        • Luna J.
        • Plata M.
        • Gonzalez M.
        • et al.
        Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil in adult women.
        PLoS One. 2013; 8: e8343
        View in Article
        • Munoz N.
        • Manalastas Jr., R.
        • Pitisuttithum P.
        • et al.
        Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial.
        Lancet. 2009; 373: 1949-1957
        View in Article
        • Joura E.A.
        • Garland S.M.
        • Paavonen J.
        • Ferris D.G.
        • Perez G.
        • Ault K.A.
        • Huh W.K.
        • Sings H.L.
        • James M.K.
        • Haupt R.M.
        Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.; FUTURE I and II study group.
        BMJ. 2012 Mar 27; e1401: 344
        View in Article
        • Swedish K.A.
        • Factor S.H.
        • Goldstone S.E.
        Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study.
        Clin. Infect. Dis. 2012 Apr; 54: 891-898
        View in Article
        • Deshmukh A.
        • Cantor S.B.
        • Fenwick E.
        • Chiao E.Y.
        • Nyitray A.G.
        • Strier E.A.
        • Goldstone S.E.
        • Wilkin T.
        • Chhatwal J.
        Adjuvant HPV vaccination for anal cancer prevention in HIV-positive men who have sex with men: the time is now.
        Vaccine. 2017 Sep 12; 35: 5102-5109
        View in Article
        • Kin Cho Goon P.
        • Sholtz L.U.
        • Sudhoff H.
        Recurrent respiratory papillomatosis (RRP)-time for a reckoning?.
        Laryngoscope Investig. Otolaryngol. 2017 May 28; 2: 184-186
        View in Article
        • Swedish K.A.
        • Goldstone S.E.
        Prevention of anal condyloma with quadrivalent human papillomavirus vaccination of older men who have sex with men.
        PLoSOne. 2014 Apr 8; 9e93393
        View in Article
        • Prendiville W.
        Appropriate use of leep interventions.
        J. Low Genit. Tract. Dis. 1998 Oct; 2: 254
        View in Article
        • Kang W.D.
        • Choi H.S.
        • Kim S.M.
        Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?.
        Gynecol. Oncol. 2013 Aug; 130: 264-268
        View in Article
        • Garland S.M.
        • Paavonen J.
        • Jaisamrarn U.
        • HPV PATRICIA Study Group
        • et al.
        Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high-grade cervical intraepithelial neoplasia after definitive surgical therapy: post-hoc analysis from a randomized controlled trial.
        Int. J. Cancer. 2016; 139: 2812-2826
        View in Article
        • Hildesheim A.
        • Gonzalez P.
        • Kreimer A.R.
        • Wacholder S.
        • Schussler J.
        • Rodriguez A.C.
        • Porras C.
        • Schiffmann M.
        • Sidawy M.
        • Schiller J.T.
        • Lowy D.R.
        • Herrero R.
        • Costa Rica HPV Vaccine Trial (CVT) Group
        Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
        J. Obstet. Gynecol. 2016 Aug; 215: 212-215
        View in Article
        • Song S.H.
        • Lee J.K.
        • Lee N.W.
        • Saw H.S.
        • Kang J.S.
        • Lee K.W.
        Interferon-gamma (IFN-gamma): a possible prognostic marker for clearance of high-risk human papillomavirus (HPV).
        Gynecol. Oncol. 2008 Mar; 108: 543-548
        View in Article
        • Rosa M.I.
        • Moraes M.V.
        • Vuolo F.
        • Petronilho F.
        • Bozzetti M.C.
        • Medeiros L.R.
        • et al.
        Association of interleukin-6 in women with persistence of DNA-HPV: a nested case-control study.
        Arch. Gynecol. Obstet. 2012 Jan; 285: 143-148
        View in Article
        • Paradkar P.H.
        • Joshi J.V.
        • Mertia P.N.
        • Agashe S.V.
        • Vaidya R.A.
        Role of cytokines in genesis, progression and prognosis of cervical cancer.
        Asian Pac. J. Cancer Prev. 2014; 15: 3851-3864
        View in Article
        • Scott M.E.
        • Shvetsov Y.B.
        • Thompson P.J.
        • Hernandez B.Y.
        • Zhu X.
        • Wilkens L.R.
        • et al.
        Cervical cytokines and clearance of incident human papillomavirus infection: Hawaii HPV cohort study.
        Int. J. Cancer. 2013 Sep 1; 133: 1187-1196
        View in Article
        • Saftlas A.F.
        • Spracklen C.N.
        • Ryckman K.K.
        • Stockdale C.K.
        • Penrose K.
        • Ault K.
        • Rubenstein L.M.
        • Pinto L.A.
        Influence of a loop electrosurgical excision procedure (LEEP) on levels of cytokines in cervical secretions.
        J. Reprod. Immunol. 2015 Jun; 109: 74-83
        View in Article

      Article info

      Publication history

      Published online: September 06, 2018
      Accepted: August 25, 2018
      Received in revised form: August 21, 2018
      Received: June 29, 2018

      Identification

      DOI: https://doi.org/10.1016/j.ygyno.2018.08.033

      Copyright

      © 2018 Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX